Pharmaron, a CRO offering lab and manufacturing services, has acquired Quotient Bioresearch, a UK-based CRO focused on integrating radiochemistry and metabolism. Part of this expertise is derived from Quotient’s previous acquisition of GE Amersham’s radiosynthesis business. The acquisition expands Pharmaron’s technology platforms in chemistry, biology, DMPK, pharmacology, safety assessment, chemical and pharmaceutical development, and strengthens its service portfolio with more comprehensive ...